HIV

HIV patients lack crucial peroxisomal proteins in the brain.

Prequalification will allow countries to access generic sofosbuvir and an HIV self-test.

Response rate higher among patients with HIV treated with dolutegravir compared with lopinavir/ritonavir.

Top news of the day from across the health care landscape.

Dolutegravir-based treatment non-inferior to boosted protease inhibitor regimen in virally suppressed HIV-positive patients.

The future for pharmacy is very lucrative as they press on for provider status.

Resistance poses a global threat.

Fixed-dose combination tablet containing doravirine achieved viral suppression in HIV-1 infected treatment-naïve adults.

Immunization of cows induces rapid elicitation of broadly neutralizing antibodies to HIV.

Gilead's experimental combination therapy observed to reduce HIV RNA in adult patients.

Top news of the day from across the health care landscape.

The demand for innovation is not slowing down. 

Combination treatments well tolerated amongst study participants with HIV-1 infection.

Proper dosing of Vorinostat can help expose latent HIV.

New treatments for inflammatory conditions, cancer, and HIV are on the horizon. 

Top news of the day from across the health care landscape.

Enzyme acts as an epigenetic checkpoint of T cell function to treat cancer.

A look at the top stories in pharmacy last week.

Top articles of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Sexual risk behaviors are associated with increased HIV transmission and prevalence, yet women are largely understudied.

PrEP has been found to be effective in preventing HIV in high-risk populations.

The production of HIV-1 neutralizing antibodies correlated with self-reactive antibody levels,